{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:30:33Z","timestamp":1793035833989,"version":"4.5.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,23]]},"abstract":"<jats:p>The implementation of a treat-to-target (T2T) approach has been widely recommended for achieving optimal outcomes in gout treatment, as substantiated by a wealth of compelling evidence. However, a paucity of knowledge exists regarding the barriers hindering effective T2T management in China. This study seeks to investigate the factors contributing to treatment failure within the context of the T2T strategy. A cross-sectional, multi-center investigation was conducted, involving the completion of electronic questionnaires by outpatients undergoing urate-lowering treatment for a duration exceeding 6 months. These questionnaires encompassed demographic information, disease-related conditions, comorbid conditions, and management. The study analyzed factors associated with serum uric acid levels exceeding 360 \u00b5mol\/L, poor disease control, and poor medication adherence. A total of 425 valid questionnaires were collected, representing 90.8% of the patients. The T2T implementation rate was 26.82% (n\u2005=\u2005114). Factors linked to serum uric acid levels surpassing 360 \u00b5mol\/L included moderate medication adherence (odds ratio (OR)\u2005=\u20052.35; 95% confidence interval (CI) 1.17\u20134.77; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.016), poor medication adherence (OR\u2005=\u20054.63; 95% CI 2.28\u20139.51; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), and management by general practitioners (OR\u2005=\u20050.60; 95% CI 0.37\u20130.97; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.036). The rate of well-controlled patients was 14.35% (n\u2005=\u200561). Predictors of not well controlled encompassed the presence of tophi (OR\u2005=\u20052.48; 95% CI 1.17\u20135.61; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.023), general medication adherence (OR\u2005=\u20052.78; 95% CI 1.28\u20136.05; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.009), poor medication adherence (OR\u2005=\u20056.23; 95% CI 2.68\u201314.77; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), and poor patient\u2019s perception of gout (OR\u2005=\u20054.07; 95% CI 1.41\u201313.91; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.015). A poor medication adherence rate of 55.29% (n\u2005=\u2005235) was observed, with lower rates of poor medication adherence associated with the use of febuxostat (OR\u2005=\u20050.35; 95% CI 0.14\u20130.83; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.02), uric acid levels exceeding 360 \u00b5mol\/L (OR\u2005=\u20053.05; 95% CI 1.84\u20135.12; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.00), moderate patient education (OR\u2005=\u20052.28; 95% CI 1.29\u20134.15; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.01), moderate diet control (OR\u2005=\u20051.98; 95% CI 1.17\u20133.41; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.01), and poor diet control (OR\u2005=\u20053.73; 95% CI 1.26\u201312.83; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.02). The rate of T2T implementation in China is notably low among patients undergoing urate-lowering treatment of gout beyond 6 months. Importantly, medication adherence demonstrates a significant association with T2T outcomes.<\/jats:p>","DOI":"10.1097\/md.0000000000037228","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T21:07:19Z","timestamp":1708722439000},"page":"e37228","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Association between patient adherence and treat-to-target in gout: A cross-sectional study"],"prefix":"10.1097","volume":"103","author":[{"given":"Shasha","family":"Hu","sequence":"first","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China"},{"name":"Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihui","family":"He","sequence":"additional","affiliation":[{"name":"Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China"},{"name":"The Department of Rheumatology, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wukai","family":"Ma","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Geng","sequence":"additional","affiliation":[{"name":"The Department of Gynecology, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Caner, School of Public Health, Fujian Medical University, Fuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueming","family":"Yao","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhong","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China"},{"name":"The Department of Rheumatology, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wei","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China"},{"name":"The Department of Rheumatology, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Qiu","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China"},{"name":"The Department of Rheumatology, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-1689","authenticated-orcid":false,"given":"Ertao","family":"Jia","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China"},{"name":"The Department of Rheumatology, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008.","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors.","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"R3-20250503","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1908","article-title":"The inflammatory process of gout and its treatment.","volume":"8","author":"Cronstein","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/1756-185X.14583","article-title":"Are non-steroidal anti-inflammatory drugs safe and effective in patients with acute gout? A Cochrane review summary with commentary.","volume":"26","author":"Coskun Benlidayi","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"e19668","DOI":"10.1097\/MD.0000000000019668","article-title":"Treatment for acute flares of gout: a protocol for systematic review.","volume":"99","author":"Tang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","article-title":"Update on gout: new therapeutic strategies and options.","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout.","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout.","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout.","volume":"76","author":"Kiltz","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/acr.23347","article-title":"Dyslipidemia, alcohol consumption, and obesity as main factors associated with poor control of urate levels in patients receiving urate-lowering therapy.","volume":"70","author":"Latourte","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/ard.2007.070755","article-title":"Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.","volume":"66","author":"Roddy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis.","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00296-019-04475-6","article-title":"Burden and management of gout in a multi-ethnic Asian cohort.","volume":"40","author":"Chua","year":"2020","journal-title":"Rheumatol Int"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/rheumatology\/kex530","article-title":"Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies.","volume":"57","author":"Rai","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-018-1633-9","article-title":"Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.","volume":"20","author":"Pisaniello","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout.","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet (London, England)"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet (London, England)"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7812\/TPP\/15-234","article-title":"A pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial.","volume":"20","author":"Goldfien","year":"2016","journal-title":"Perm J"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial.","volume":"132","author":"Mikuls","year":"2019","journal-title":"Am J Med"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3233\/THC-191951","article-title":"Treat-to-target urate-lowering therapy in primary gout patients: a real-world retrospective study at a dedicated gout clinic in China.","volume":"29","author":"Bai","year":"2021","journal-title":"Technol Health Care"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14397595.2020.1800557","article-title":"Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.","volume":"31","author":"Quilisadio","year":"2021","journal-title":"Mod Rheumatol"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout.","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative.","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/03009742.2017.1350746","article-title":"Gout in a rheumatology clinic: results of EULAR\/ACR guidelines-compliant treatment.","volume":"47","author":"Slot","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting.","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s10067-016-3212-2","article-title":"Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice.","volume":"35","author":"Spaetgens","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British Society for Rheumatology guideline for the management of gout.","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/annrheumdis-2011-201215","article-title":"Purine-rich foods intake and recurrent gout attacks.","volume":"71","author":"Zhang","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/RHU.0b013e318228b4e2","article-title":"Development and evaluation of a survey of gout patients concerning their knowledge about gout.","volume":"17","author":"Zhang","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","article-title":"Gout epidemiology and comorbidities.","volume":"50","author":"Singh","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","article-title":"Medication adherence in gout: a systematic review.","volume":"66","author":"De Vera","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"e8532","DOI":"10.1097\/MD.0000000000008532","article-title":"Adherence to gout management recommendations of Chinese patients.","volume":"96","author":"Sheng","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/rheumatology\/key155","article-title":"Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).","volume":"57","author":"Scheepers","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1111\/jocn.13918","article-title":"Factors influencing medication adherence in patients with gout: a descriptive correlational study.","volume":"27","author":"Chua","year":"2018","journal-title":"J Clin Nurs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:31:30Z","timestamp":1746318690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037228","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]}}}